Scalper1 News
BioMarin Pharmaceutical (BMRN) stock rose 11.5% to an all-time high Friday on heavy volume as speculation builds that the company could be the next big biotech takeout. The stock jumped as investment bank UBS raised its price target on BioMarin Pharmaceutical stock to 136 from 112. Deutsche Bank also raised its price target on Friday, to 140 from 90, and an analyst for the investment bank suggested that BioMarin might make an attractive target, Scalper1 News
Scalper1 News